258 related articles for article (PubMed ID: 30454693)
1. Peripheral blood inflammatory markers in early Parkinson's disease.
Kim R; Kim HJ; Kim A; Jang M; Kim A; Kim Y; Yoo D; Im JH; Choi JH; Jeon B
J Clin Neurosci; 2018 Dec; 58():30-33. PubMed ID: 30454693
[TBL] [Abstract][Full Text] [Related]
2. Association of Parkinson's disease-related pain with plasma interleukin-1, interleukin-6, interleukin-10, and tumour necrosis factor-α.
Li D; Song X; Huang H; Huang H; Ye Z
Neurosci Lett; 2018 Sep; 683():181-184. PubMed ID: 30063943
[TBL] [Abstract][Full Text] [Related]
3. Serum Inflammatory Markers and Progression of Nonmotor Symptoms in Early Parkinson's Disease.
Kim R; Kim HJ; Shin JH; Lee CY; Jeon SH; Jeon B
Mov Disord; 2022 Jul; 37(7):1535-1541. PubMed ID: 35596676
[TBL] [Abstract][Full Text] [Related]
4. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson's disease.
Fan Z; Pan YT; Zhang ZY; Yang H; Yu SY; Zheng Y; Ma JH; Wang XM
J Neuroinflammation; 2020 Jan; 17(1):11. PubMed ID: 31915018
[TBL] [Abstract][Full Text] [Related]
5. Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum.
Lindqvist D; Kaufman E; Brundin L; Hall S; Surova Y; Hansson O
PLoS One; 2012; 7(10):e47387. PubMed ID: 23082161
[TBL] [Abstract][Full Text] [Related]
6. Selected serum cytokines and nitric oxide as potential multi-marker biosignature panels for Parkinson disease of varying durations: a case-control study.
Rathnayake D; Chang T; Udagama P
BMC Neurol; 2019 Apr; 19(1):56. PubMed ID: 30954070
[TBL] [Abstract][Full Text] [Related]
7. Peripheral inflammatory cytokines and motor symptoms in persons with Parkinson's disease.
Diaz K; Kohut ML; Russell DW; Stegemöller EL
Brain Behav Immun Health; 2022 May; 21():100442. PubMed ID: 35308082
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment.
Lindqvist D; Hall S; Surova Y; Nielsen HM; Janelidze S; Brundin L; Hansson O
Brain Behav Immun; 2013 Oct; 33():183-9. PubMed ID: 23911592
[TBL] [Abstract][Full Text] [Related]
9. Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease.
Lin CH; Chen CC; Chiang HL; Liou JM; Chang CM; Lu TP; Chuang EY; Tai YC; Cheng C; Lin HY; Wu MS
J Neuroinflammation; 2019 Jun; 16(1):129. PubMed ID: 31248424
[TBL] [Abstract][Full Text] [Related]
10. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).
Williams-Gray CH; Wijeyekoon R; Yarnall AJ; Lawson RA; Breen DP; Evans JR; Cummins GA; Duncan GW; Khoo TK; Burn DJ; Barker RA;
Mov Disord; 2016 Jul; 31(7):995-1003. PubMed ID: 26999434
[TBL] [Abstract][Full Text] [Related]
11. Plasma IL-6 and IL-17A Correlate with Severity of Motor and Non-Motor Symptoms in Parkinson's Disease.
Green HF; Khosousi S; Svenningsson P
J Parkinsons Dis; 2019; 9(4):705-709. PubMed ID: 31524180
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-α levels in CSF and serum in relation to the clinical diversity of Parkinson's disease.
Karpenko MN; Vasilishina AA; Gromova EA; Muruzheva ZM; Miliukhina IV; Bernadotte A
Cell Immunol; 2018 May; 327():77-82. PubMed ID: 29478949
[TBL] [Abstract][Full Text] [Related]
13. Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis.
Qin XY; Zhang SP; Cao C; Loh YP; Cheng Y
JAMA Neurol; 2016 Nov; 73(11):1316-1324. PubMed ID: 27668667
[TBL] [Abstract][Full Text] [Related]
14. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study.
Delgado-Alvarado M; Gago B; Gorostidi A; Jiménez-Urbieta H; Dacosta-Aguayo R; Navalpotro-Gómez I; Ruiz-Martínez J; Bergareche A; Martí-Massó JF; Martínez-Lage P; Izagirre A; Rodríguez-Oroz MC
Mov Disord; 2017 Jul; 32(7):1066-1073. PubMed ID: 28548309
[TBL] [Abstract][Full Text] [Related]
15. Circulating interleukin-10 and interleukin-12 in Parkinson's disease.
Rentzos M; Nikolaou C; Andreadou E; Paraskevas GP; Rombos A; Zoga M; Tsoutsou A; Boufidou F; Kapaki E; Vassilopoulos D
Acta Neurol Scand; 2009 May; 119(5):332-7. PubMed ID: 18976327
[TBL] [Abstract][Full Text] [Related]
16. Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.
Eidson LN; Kannarkat GT; Barnum CJ; Chang J; Chung J; Caspell-Garcia C; Taylor P; Mollenhauer B; Schlossmacher MG; Ereshefsky L; Yen M; Kopil C; Frasier M; Marek K; Hertzberg VS; Tansey MG
J Neuroinflammation; 2017 Aug; 14(1):164. PubMed ID: 28821274
[TBL] [Abstract][Full Text] [Related]
17. Cytokine Profile in Plasma Extracellular Vesicles of Parkinson's Disease and the Association with Cognitive Function.
Chan L; Chung CC; Chen JH; Yu RC; Hong CT
Cells; 2021 Mar; 10(3):. PubMed ID: 33803292
[TBL] [Abstract][Full Text] [Related]
18. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson's disease.
Menza M; Dobkin RD; Marin H; Mark MH; Gara M; Bienfait K; Dicke A; Kusnekov A
Psychosomatics; 2010; 51(6):474-9. PubMed ID: 21051678
[TBL] [Abstract][Full Text] [Related]
19. Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients.
Santiago JA; Potashkin JA
PLoS One; 2015; 10(11):e0142582. PubMed ID: 26566043
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal Fluid C-Reactive Protein in Parkinson's Disease: Associations with Motor and Non-motor Symptoms.
Sanjari Moghaddam H; Valitabar Z; Ashraf-Ganjouei A; Mojtahed Zadeh M; Ghazi Sherbaf F; Aarabi MH
Neuromolecular Med; 2018 Sep; 20(3):376-385. PubMed ID: 29980980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
